澳門科技大學
MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY

醫學部 MSD

精準再生醫學研究中心
Precision Regenerative Medicine Research Centre

# 國際精準再生醫學研討會2025

## *International Precision Regenerative Medicine Symposium 2025*

**2025.12.18 中國・澳門**

時間/Time： **9:00-15:40**

**澳門科技大學N座圖書館大樓N101**

Room N101, N Block, Macau University of Science and Technology

# 目錄 / Contents

## 研討會簡介
## Symposium Introduction

精準再生醫學中心持續追求卓越，致力於融合再生醫學、免疫學及人工智能的創新研究。專注於推進對幹細胞分化、增殖與組織再生的理解。中心結合免疫調控、中藥研究與人工智能輔助藥物設計，致力發現能促進組織修復與功能恢復的新型小分子及治療策略。透過這些研究方向，中心致力於推動基礎科學成果的臨床轉化，為再生醫學提供新的治療策略。

經過兩年的發展，中心已與多所國際學術機構建立合作，獲得澳門科學技術發展基金（FDCT）多項支持，並推動科研成果的臨床應用。繼 2023 與 2024 年研討會成功舉辦後，2025 國際精準再生醫學研討會 將再度匯聚全球頂尖學者及產業專家，共同探討再生醫學的最新突破與轉化前景。

今年的研討會設有三大主題：

· 精準與再生肝膽醫學

· 發育與基因再生基礎

· 再生醫學轉化前沿

其中「轉化前沿」專場特設專題座談，邀請業界領袖共同探討幹細胞與再生醫學技術創新及臨床安全保障體系的構建。本場次為科研人員、臨床專家與產業創新者提供了寶貴的交流契機，共同探討如何將科學發現轉化為臨床應用。這將是一個充滿啟發與互動的盛會，讓與會者在分享知識與創新思維的同時，攜手推動全球再生醫學的發展。

Inaugurated in 2023 under the Medical Sciences Division (MSD), the Precision Regenerative Medicine Centre (PRMRC) aims to integrate cross-disciplinary expertise in regenerative biology, bioengineering, and precision medicine. The Precision Regenerative Medicine Centre continues to strive for excellence in advancing the understanding of stem cell differentiation, proliferation, and tissue regeneration. By integrating immune regulation, traditional Chinese medicine, and artificial-intelligence-assisted drug design, the Centre aims to discover novel small molecules and therapeutic strategies that restore function and promote tissue repair. Through these efforts, the PRMRC aims to bridge basic discovery with translational application, contributing to new therapeutic strategies for regenerative medicine.

Building on the success of the 2023 and 2024 symposia, the 2025 International Precision Regenerative Medicine Symposium brings together world-leading scientists and industry experts to share cutting-edge advances and explore pathways for clinical translation and innovation.

This year's symposium features three thematic sessions:

-Precision and Regenerative Hepatobiliary Medicine

-Developmental and Genetic Foundations of Regeneration

-Translational Frontiers in Regenerative Medicine

The Translational Frontiers session will conclude with a panel discussion featuring industry leaders on building safe and effective systems for stem-cell and regenerative medicine technologies. This session offers a valuable opportunity for researchers, clinicians, and industry innovators to exchange ideas, explore collaborations, and discuss how scientific discovery can be translated into real-world therapies. It promises to be an engaging and enjoyable occasion for all participants to share knowledge, inspire innovation, and strengthen the global community in regenerative medicine.

# 醫學部
## Medical Sciences Division (MSD)

澳門科技大學(MUST) 的醫學部(MSD) 成立於2022 年9 月，是一個充滿活力和創新的研究和教育平臺，專注於以現代科學方法促進人類健康。醫學部由中醫藥學院、醫學院(藥學院納入醫學院)、醫學人工智慧研究所、精準再生醫學研究中心、醫學部實驗室、臨床試驗中心、轉化醫學動物實驗室及天然藥物發現和產業化實驗室組成。中藥機制與質量研究國家重點實驗室及科大醫院將在教學、科研等方面持續助力醫學部的發展。

中藥機制與質量研究國家重點實驗室是中國第一個致力於中藥領域的國家重點實驗室。其研究集中在兩個主要方向：用於草藥和中藥化合物的質量控制和優化的創新技術和方法，以及用於開發高質量新型中藥的關鍵技術和質量標準。該實驗室目前由十個研究實驗室和研究中心組成，其中包括由諾貝爾獎得獎者，埃爾文．內爾教授主管的「埃爾文內爾博士生物物理與創新藥物實驗室」。

中醫是中國傳統文化中的寶藏並逐漸成為現代醫療體系中的重要組成部分。澳門適逢發展中醫藥的最佳契機，國家大力支持澳門發展中醫藥，將其納入國家十三五發展規劃，陸續出臺一系列政策支持中醫藥發展。中醫藥學院成立於2000年，提供完整的學位課程體系，為澳門中醫藥的可持續發展奠定了堅實的基礎。

醫學院提供澳門唯一的內外全科醫學學士學位課程(MBBS)，旨在為澳門培養具有同理心、人文關懷並能提供高效和優質醫療服務的「明日良醫」，醫學院醫學模擬培訓中心和醫療及衛生持續培訓中心，致力開展高質量的本科醫學培訓和持續醫學教育，改善澳門醫療保健服務。藥學院創建於2016年，是澳門特區政府唯一認可開辦藥學學士學位課程以及藥學博士學位課程的藥學專門教育機構，促進澳門醫院臨床合理用藥及管理、高水準藥物科學研究、以及醫藥產業發展等各方面的進步。

澳門科技大學的醫學部致力於推動創新、跨學科合作、卓越的研究和教育，以推進醫學科學領域的發展，改善人類健康。

The Medical Sciences Division (MSD) of the Macau University of Science and Technology (MUST) was established in September 2022 as a dynamic and innovative research and education platform focusing on modern scientific approaches to promote human health. The MSD consists of the Faculty of Chinese Medicine and the Faculty of Medicine with the School of Pharmacy integrated into the Faculty of Medicine, as well as the newly established Institute for AI in Medicine, Precision Regenerative Medicine Research Center, MSD Lab, Clinical Trial Center, Translational Medicine Animal Laboratory and Lab for Drug Discovery from Natural Resource. The State Key Laboratory of Quality Research in Chinese Medicine and University Hospital work closely with the Medical Sciences Division and support its development.

The State Key Laboratory of Quality Research in Chinese Medicine is the first State Key Laboratory in China dedicated to the field of Chinese Medicine. Its research focuses on two main directions: the innovative technologies and methods for quality controls and optimization of herbal medicines and Chinese medicine compounds, as well as the key techniques and quality standards for the development of high-quality new Chinese medicinal drugs. The laboratory currently consists of eight research laboratories and research centers, including the "Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery," a Nobel laureate workstation.

Chinese Medicine is a treasure in traditional Chinese culture and is becoming an important part of the modern medical system. The Faculty of Chinese Medicine is committed to promoting the development of Chinese Medicine and is listed into the 13th Five-Year Plan of the Chinese government. The Faculty of Chinese Medicine was established in 2000 and offers a complete degree program system, laying a solid foundation for the sustainable development of Chinese Medicine in Macau.

The Faculty of Medicine joined forces with the School of Pharmacy recently to strengthen the basis for pharmaceutical and clinical teaching and research. The Faculty of Medicine offers the only comprehensive Bachelor of Medicine and Bachelor of Surgery (MBBS) course in Macau, aiming to train tomorrow's doctors who are skilled, confident, and caring. The Faculty also established the Center for Medical Education in Medical Simulation and the Center for Continuing Medical and Health Education to promote professional development and continuing education for medical professionals. The School of Pharmacy at Macau University of Science and Technology was established in 2016. It is the only educational institution that offers both bachelor and doctoral degree in pharmacy authorized by the Macao S.A.R. government providing students with training to understand the comprehensive range of explicit uses of drugs in pharmaceutical research and an opportunity to join in drug discovery and development.

The MSD of MUST is dedicated to promoting innovation, interdisciplinary collaboration, and excellence in research and education to advance the field of medical sciences and improve human health.

# 精準再生醫學研究中心
## Precision Regenerative Medicine Research Centre (PRMRC)

精準醫學和再生醫學的急速進展為疾病的診斷和治療提供了全新的概念和方向。通過整合交叉學科優勢，以西醫和中醫臨床實踐為基礎，以轉化應用為重點，澳門科技大學醫學部（MUST-MSD）成立了“澳科大-精準再生醫學研究中心 (PRMRC)”，協調精準再生醫學的臨床基礎科研和創新應用。團隊由國內外傑出科學家組成，在譚廣亨講座教授帶領下，旨在通過國際領先的創新科研及人才培養，解決澳門和國家的一些重大健康和社會需求。

中心將為澳科大校內外再生醫學創新研究領域提供一系列前沿和尖端的技術平臺。中心的一個研究方向是對人類健康有廣泛影響的慢性纖維化肝病。基於該團隊在再生醫學（包括幹細胞和類器官發育）方面的長期研究，中心確定了兒童（以膽道閉鎖為例）和成人（以非酒精性脂肪性肝病為例）的慢性纖維化肝病作為其初始目標。重點將放在理解雙潛能肝幹細胞（dual-potential hepatic stem cells，HSCs）的在生理及病理狀態下的分化、增值、形成類器官的能力及其調控，進一步發掘相關信號通路在修復肝損傷和促進肝再生中的核心作用，並將這些知識應用於慢性肝病導致的肝纖維化的治療。

團隊的研究領域包括：

1)不同病因導致慢性纖維化對HSCs的分化、增值的調控及生物標記物發掘

2)肝臟免疫系統改變對HSCs再生能力的影響

3)肝臟星狀細胞啟動對HSCs的分化及增值影響機制研究

4)針對治療靶點、通路篩選中藥分離小分子促進HSCs再生功能的研究

5)人工智慧輔助藥物設計合成新型小分子用於改善及逆轉受損的HSCs

Advances in precision and regenerative medicines are providing new insights and directions for disease diagnosis and treatment. By integrating the cross-disciplinary advantages, the clinical foundation in western and Chinese medicines and the emphasis on translation, the MUST Medical Science Division (MSD) has established the "MUST - Precision Regenerative Medicine Research Centre (PRMRC)" to coordinate the basic clinical scientific research and innovative application of precision regenerative medicine. The team consisting of prominent scientists led by Chair Professor Paul Tam aims to solve some of the major health and society needs of Macau and the country through internationally recognized discoveries and talent-nurturing.

The centre will provide an array of frontier and beyond-cutting-edge technology platforms for wide-ranging novel regenerative medicine studies within and outside MUST. A prioritized direction of the Centre targets chronic fibrotic liver disease that has a wide impact on human health. Based on the team's long-term research in regenerative medicine including stem cells and organoids development, the Centre has identified chronic fibrotic liver disease in children (with biliary atresia as an example) and adults (with non-alcoholic fatty liver disease as an example) as its initial goals. Emphasis will be placed on understanding the regulation of differentiation, proliferation and the formation of liver organoids of dual-potential hepatic stem cells (HSCs), which play a central role in repairing liver damage and promoting regeneration, with the expectation that the new knowledge can be applied in the treatment of chronic liver fibrosis and liver regeneration.

The research areas of the team include:

1)Regulation of differentiation and proliferation of HSCs in chronic fibrosis under different ethnologies

2)Effects of liver immune system changes on regeneration capacity of HSCs

3)Mechanism of hepatic stellate cell activation on differentiation and proliferation of HSCs

4)Small molecules isolated from traditional Chinese medicine (TCM) promote regeneration of HSCs

5)Artificial intelligence (AI) assisted drug design and synthesis of novel small molecules for improving and reversing damage

## 大健康醫學研發及成果轉化中心
## Centre for Healthy Medical R&D and Translation

2024 年 4 月，澳門科技大學在橫琴粵澳深度合作區設立「澳門科技大學創新科技研究院」。

研究院下設「大健康醫學研發及成果轉化中心」（以下簡稱「中心」），由譚廣亨教授領銜的澳科大精準再生醫學研究中心（PRMRC）牽頭，並聯合研究院其他實驗室， 包括：中藥機制與質量研究國家重點實驗室（橫琴分部）；月球與行星科學國家重點實驗室（橫琴分部）及若幹校級前沿實驗室（橫琴分部）共同構建「琴澳協同、轉化導向」的科研高地。

In April 2024, Macau University of Science and Technology established the “MUST Institute of Innovation & Technology” in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin.

The Institute hosts the “Centre for Healthy Medical R&D and Translation” (hereinafter “the Centre”), led by the MUST Precision Regenerative Medicine Research Centre (PRMRC) under Prof. Tam Kwong-Hang, in conjunction with other laboratories of the Institute, including: the State Key Laboratory of Quality Research in Chinese Medicine (Hengqin Branch); the State Key Laboratory of Lunar and Planetary Sciences (Hengqin Branch); and several university-level frontier laboratories (Hengqin Branches), jointly building a “Hengqin-Macao synergy, translation-oriented” research highland.

## 兩大功能板塊
## Two Core Platforms

| 板 塊 / Platform | 定 位 / Focus | 核心能力 / Key Capabilities |
|---|---|---|
| 分子生物醫學實驗室<br>Molecular Biomedicine Laboratory | 臨床樣本驅動的幹細胞與類器官研究<br>Patient-sample-driven stem-cell &organoid R&D | • 細胞培養室<br>Cell-culture room<br>• 完整分子生物學平臺<br>Full molecular-biology platform<br>• 藥物篩選模型開發與驗證<br>Drug-screening model development & validation |
| 大資料分析中心<br>Big-Data Analytics Hub | 疾病多組學資料採擷與靶點發現<br>Multi-omics mining & target discovery | • 單細胞測序解析<br>Single-cell sequencing analytics<br>• AI 輔助靶點預測<br>AI-assisted target prediction<br>• 療效評估與機制驗證<br>Efficacy evaluation & mechanistic validation |

## 協同創新閉環
## Integrated Innovation Loop

- 橫琴實驗室聚焦「臨床問題—幹細胞/類器官模型—藥物篩選—資料回饋」的轉化路徑；
  The Hengqin site focuses on the translational pipeline “clinical problem → stem-cell/organoid model → drug screening → data feedback”;
- 澳門本部實驗室深耕「細胞/動物機制—靶點發現—早期評價」的基礎研究；
  The Macao headquarters investigates into basic research “cell/animal mechanism → target discovery → early assessment” ;
- 兩地資源互補，形成「從機制到臨床」的完整創新鏈條，加速精準再生醫學成果落地。
  Complementary resources at the two locales forge a full “mechanism-to-clinic” innovation chain, accelerating the translation of precision regenerative medicine achievements.

## 活動流程
Rundown

| 時 間 | 活 動 |
|---|---|
| **開幕儀式** | |
| 9:00 ~ 9:10 | • **致歡迎辭:**<br>譚廣亨 講座教授(香港科學院院士；澳門科技大學副校長、精準再生醫學研究中心總監)<br>• **開幕致辭:**<br>余雨生 博士 (澳門科學技術發展基金行政委員會主席)<br>• **嘉賓和全場大合照** |
| **第一部分：精準與再生肝膽醫學** | |
| **主持人：潘星華教授(澳門科技大學)、黃耀南助理教授(澳門科技大學)** | |
| 9:10 ~ 9:40 | 【再生醫學在小兒外科的轉化應用：進展與挑戰】<br>演講者： **Paolo De Coppi 教授**<br>（倫敦大學學院大奧蒙德街兒童健康研究所） |
| 9:40 ~ 10:10 | 【肝臟腫瘤發生的分子機制】<br>演講者： **Richard Thompson 教授**<br>(倫敦國王學院) |
| 10:10 ~ 10:40 | 【肝病再生醫學的進展】<br>演講者： **Fotios Sampaziotis 教授**<br>(劍橋大學) |
| 10:40 ~ 10:55 | 茶歇 |
| **第二部分: 再生醫學的發展與遺傳基礎** | |
| **主持人：呂志恒副教授（香港大學）、蒙梓棋助理教授(澳門科技大學)** | |
| 10:55 ~ 11:25 | 【代謝失調相關脂肪性肝病的基因學研究與RNA干預藥物的開發】<br>演講者： **Huck – Hui Ng 教授**<br>(新加坡科技研究局) |
| 11:25 ~ 11:55 | 【骨骼架構藍圖：骨細胞譜系及其微環境的遺傳與發育調控】<br>演講者： **謝賞恩 教授**<br>(香港科學院院士；香港大學) |
| 11:55 ~ 12:25 | 【結合再生醫學，多組學及人工智能平台開展改善慢性肝病纖維化的標靶發現及精準干預新診療 進度報告】<br>**演講者： 譚廣亨 講座教授**<br>（香港科學院院士；澳門科技大學副校長、精準再生醫學研究中心總監 代表AKP團隊） |

## 活動流程
Rundown

| 時 間 | 活 動 |
|---|---|
| 10:40 ~ 10:55 | 午餐 |
| **第三部分：再生醫學的轉化前沿** | |
| 主持人：朱依諄講座教授（歐洲科學與藝術學院院士）、余梓山總監（澳門科技大學） | |
| 14:00 ~ 14:10 | 【幹細胞與再生醫學技術革新與臨床安全保障體系構建】<br>演講者：**文學軍 教授**<br>（維吉尼亞聯邦大學） |
| 14:00 ~ 14:10 | 【幹細胞治療引領再生醫學領域的新時代】<br>演講者：**羅雲 先生** (眾生集團；成都拜美森生物科技有限公司)<br>**尚進 博士** (成都拜美森生物科技有限公司) |
| 14:20 ~ 14:30 | 【新生兒臍帶帶幹細胞在再生與長壽醫學的應用】<br>演講者：**潘全勝 副教授**<br>（新加坡國立大學） |
| 14:30 ~ 14:40 | 【CAR-T療法的進展：從自體細胞到體內載體遞送的研究前沿】<br>演講者：**林成龍 教授**<br>（臺灣沛爾生技醫藥股份有限公司） |
| 14:40 ~ 14:50 | 【調節性T細胞療法在自身免疫疾病的突破探索】<br>演講者：**劉峰 博士**<br>（博迪賀康(北京)生物技術有限公司） |
| 14:50 ~ 15:00 | 【個性化mRNA 腫瘤疫苗的開發和應用】<br>演講者：**陳立 博士**<br>（北京立康生命科技有限公司） |
| 15:00 ~ 15:30 | 【專家座談會】先進治療藥物產品的臨床轉化與應用<br>– 文學軍 教授 (維吉尼亞聯邦大學)<br>– 林成龍 教授（臺灣沛爾生技醫藥股份有限公司）<br>– 潘全勝 副教授 (新加坡國立大學)<br>– 羅雲 先生 (眾生集團；成都拜美森生物科技有限公司)、尚進 博士 (成都拜美森生物科技有限公司)<br>– 劉峰 博士 (博迪賀康(北京)生物技術有限公司)<br>– 陳立 博士 (北京立康生命科技有限公司) |
| 15:30 ~ 15:40 | 【政策賦能：澳門大健康產業的營商優勢與機遇】<br>演講者：**簡婉君 小姐**<br>（澳門特別行政區政府招商投資促進局招商投資促進處職務主管） |
| 15:40 ~ 17:30 | **參觀澳門名勝 (受邀嘉賓)**<br>澳門科技大學 – 路環漁韻 – 官也街 – 晚宴地點 |
| 18:30 | 晚宴<br>地點：金悅軒（大中華廣場店） |

## 活動流程
## Rundown

| Time | Event |
|---|---|
| | **Opening Ceremony** |
| 9:00 ~ 9:10 | • **Welcoming remarks:**<br>Chair Prof. Paul Kwong-Hang Tam (Member of ASHK; Vice President of MUST; Director of PRMRC)<br>• **Opening Addresses:**<br>Dr. Vincent U Sang U (President of the Administrative Committee of FDCT)<br>• **Group Photo** |
| | **Session 1: Precision and Regenerative Hepatobiliary Medicine** |
| | **Moderator: Prof. Victor Xinghua Pan (MUST); Asst. Prof. Steve Io Nam Wong (MUST)** |
| 9:10 ~ 9:40 | **【Translating Regenerative Medicine into Paediatric Surgery: Achievements and Challenges】**<br>**Prof. Paolo De Coppi**<br>(UCL Great Ormond Street Institute of Child Health) |
| 9:40 ~ 10:10 | **【Insights into tumour formation in the liver】**<br>**Prof. Richard Thompson**<br>(King's College London) |
| 10:10 ~ 10:40 | **【Advances in Regenerative Medicine for Liver Disease】**<br>**Prof. Fotios Sampaziotis**<br>(University of Cambridge) |
| 10:40 ~ 10:55 | **Tea break** |
| | **Session 2: Developmental and Genetic Foundations of Regeneration** |
| | **Moderator: Assoc. Prof. Vincent Chi Hang Lui (University of Hong Kong) ; Asst. Prof. Olivia De Souza Monteiro (MUST)** |
| 10:55 ~ 11:25 | **【Genomics of Metabolic Dysfunction-associated Steatotic Liver Disease and discovery of RNA drugs as interventions】**<br>**Prof. Huck-Hui Ng**<br>(Genome Institute of Singapore) |
| 11:25 ~ 11:55 | **【The Blueprint of Bone Architecture: Genetic and Developmental Control of skeletal Cell lineages and Neighborhoods】**<br>**Prof. Kathryn Song Eng Cheah**<br>(Member of ASHK; University of Hong Kong) |
| 11:55 ~ 12:25 | **【FDCT AKP Progress Report】**<br>**Chair Prof. Paul Kwong-Hang Tam**<br>(Member of ASHK; Vice President of MUST; Director of PRMRC on behalf of AKP team) |

## 活動流程
## Rundown

| Time | Event |
|---|---|
| 12:25 ~ 14:00 | Lunch at Seasons Restaurant |
| | Session 3: Translational Frontiers in Regenerative Medicine |
| | Moderator: Chair Prof. Yi Zhun Zhu (Member of EurASc); Director Hailson Tze Shan Yu (MUST) |
| 14:00 ~ 14:10 | 【Building a Safe and Efficacy System for Stem Cell Technologies】<br>**Prof. Xuejun Wen**<br>(Virginia Commonwealth University) |
| 14:10 ~ 14:20 | 【Stem Cell Therapy: Leading a New Era in Regenerative Medicine】<br>**Mr. Yun Luo** (Zhongsheng Group; Chengdu Biomason Biotechnology Co., Ltd.)<br>**Dr. Jin Shang** (Chengdu Biomason Biotechnology Co., Ltd.) |
| 14:20 ~ 14:30 | 【Neonatal Stem Cells derived From Umbilical Cord Tissue for Regenerative and Longevity Medicine】<br>**Assoc. Prof. Toan Thang Phan** (National University of Singapore) |
| 14:30 ~ 14:40 | 【Advances in CAR-T development ---from autologous cells to in vivo vehicle delivery】<br>**Prof. Steve Chen Lung Lin**<br>(Pell Bio Med Technology Co., Ltd.) |
| 14:40 ~ 14:50 | 【The Exploration of Treg-based Immuno-therapies for Autoimmune Diseases】<br>**Dr. Tony Feng Liu**<br>(Benethera Biotechnology) |
| 14:50 ~ 15:00 | 【Personalized mRNA Tumour Vaccines: From Development to Clinical Use】<br>**Dr. Li Chen**<br>(Likang Life Sciences) |
| 15:00 ~ 15:30 | 【Panel Discussion Session: Bringing Advanced Therapy Medicinal Products to the Clinic】<br>- Prof. Xuejun Wen (Virginia Commonwealth University)<br>- Prof. Steve Chen Lung Lin (Pell Bio Med Technology Co., Ltd.)<br>- Assoc. Prof. Toan Thang Phan (National University of Singapore)<br>- Mr. Yun Luo (Zhongsheng Group; Chengdu Biomason Biotechnology Co., Ltd.) & Dr. Jin Shang (Chengdu Biomason Biotechnology Co., Ltd.)<br>- Dr. Tony Feng Liu (Benethera Biotechnology)<br>- Dr. Li Chen (Likang Life Sciences) |
| 15:30 ~ 15:40 | 【Policy Empowerment: The Business Advantages and Opportunities of Macao's Health Industry】<br>**Ms. Irene Kan**<br>(Functional Head of Investment Promotion Division of Macao Commerce and Investment Promotion Institute) |
| 15:30 ~ 17:30 | For Invited Guests: Visiting Local Attractions<br>MUST – Coloane Fishing Village – Rua Do Cunha – Gala Dinner Venue |
| 18:30 | Gala Dinner<br>Venue: Jinyuexuan |

# 講者簡介
## Speaker Biography

### 【再生醫學在小兒外科的轉化應用：進展與挑戰】
【Translating Regenerative Medicine into Paediatric Surgery: Achievements and Challenges】

**Paolo De Coppi 教授**
Prof. Paolo De Coppi

倫敦大學學院大奧蒙德街兒童健康研究所
UCL Great Ormond Street Institute of Child Health

Paolo de Coppi 教授現任倫敦大奧蒙德街醫院(GOSH)顧問小兒外科醫生，同時擔任倫敦大學學院兒童健康研究所幹細胞與再生醫學講座教授暨部門主管。

自2013年起，他擔任比利時魯汶天主教大學榮譽教授；自2009年起，擔任北卡羅來納州溫斯頓–塞勒姆市維克森林大學維克森林再生醫學研究所兼任助理教授；自2005年起，擔任義大利帕多瓦大學小兒外科榮譽助理教授。

他主要研究微創技術和相應的治療手段。他的研究為兒童帶來了許多突破性的新療法。保羅•德•科皮教授對先天畸形及其微創技術治療特別感興趣。他的研究興趣集中在幹細胞和組織工程上，並試圖尋找治療複雜先天異常的新方法。在美國波士頓兒童醫院工作期間，他發現了一種能應用於治療的新細胞來源，他的研究結果顯示了使用羊水幹細胞的可能性。這項發現使他獲得了一項國際專利，相應的成果也成為 2007年1月《自然–生物技術》期刊的封面故事。他也因探索使用這些細胞治療先天畸形的可能性而獲得了很多研究資助。他最近專注於開發臨床水平（GMP級）幹細胞分離、擴增和分化的可靠方法。在2010年，他作為團隊的其中一員，在大奧蒙德街醫院為一名兒童成功進行了首宗利用組織工程改造的氣管移植手術。

他在The Lancet、Nature Biotechnology、PNAS等期刊上發表了240多篇同行評審文章； 指導研究員、博士學生40餘名，並已獲得超過2300萬英鎊的各種國家級或國際級研究經費。同時，他是《小兒外科期刊》、《國際小兒外科期刊》和《胎兒和孕產婦醫學評論》的期刊編委會成員。自2011年起，他更出任幹細胞轉譯醫學領域權威期刊《幹細胞轉譯醫學》資深編輯。

Prof. Paolo De Coppi is a Consultant Paediatric Surgeon at Great Ormond Street Hospital (GOSH), and Reader and Head of Stem Cells and Regenerative Medicine at the UCL Institute of Child Health in London.

He has been an Honorary Professor at the Katholieke Universiteit Leuven, Belgium, since 2013, an Adjunct Assistant Professor at the Wake Forest Institute for Regenerative Medicine, Wake Forest University in Winston-Salem, North Carolina, since 2009 and an Honorary Assistant Professor in Paediatric Surgery at the University of Padua, Italy, since 2005.

He has a special interest in research and treatments using minimally invasive techniques. His research has led to many ground-breaking new treatments for children. Professor de Coppi has a special interest in congenital malformation and their treatment using minimally invasive techniques. He has focused his research interests on stem cells and tissue engineering, trying to find new modalities for the treatment of complex congenital anomalies. While working at the Childrens' Hospital in Boston-US, he had the opportunity of identifying a new source of cells for therapeutic applications showing the possibility of using stem cells from amniotic fluid. This finding generated an international patent and garnered the cover story of *Nature Biotechnology* in January 2007. He has received funding for exploring the possibility of using these cells for the treatment of congenital malformations. He has more recently focused on developing reliable methods for stem cell isolation, expansion and differentiation at a clinical level (GMP-grade). Finally, in 2010 he was part of the team that performed the first successful transplantation of a tissue-engineered trachea on a child at the Great Ormond Street Hospital.

He has published more than 240 peer-reviewed articles in journals such as The Lancet, Nature Biotechnology, PNAS; supervised more than 40 research fellow and Ph.D. students; and has been awarded various national and international grants in excess of £23 million. He is on the editorial boards of the Journal of *Pediatric Surgery, Pediatric Surgery International*, and *Fetal and Maternal Medicine Review*. As of 2011 he has been Senior Editor for *Stem Cell Translational Medicine,* a lead journal in the field of translational stem cells.

# 講者簡介
## Speaker Biography

**【肝臟腫瘤發生的分子機制】**
【Insights into tumour formation in the liver】

**Richard Thompson 教授**
Prof. Richard Thompson

倫敦國王學院分子肝病學教授
Professor of Molecular Hepatology, King's College London

Richard Thompson是倫敦國王學院分子肝病學教授。過去30年間，他持續致力於成人與兒童肝臟疾病的研究。其研究團隊已鑒定出多個與膽汁淤積相關的基因，並進一步確立了早發性與晚發性疾病中的表型/基因型關聯。隨後他主導了多項針對這些疾病的關鍵性治療試驗。該團隊運用遺傳學方法，深入探究了各類肝臟疾病的病因、併發症及治療反應機制。

Richard Thompson is the professor of Molecular Hepatology and King's College London. He has been investigating liver disease, in adults and children, for the last 30 years. His group has identified several genes involved in cholestasis. He has gone on to establish phenotype/genotype relationships in both early and late onset disease. He has subsequently lead several pivotal trials in the treatment of these diseases. His group have used genetics to investigate causes, complications and response to treatment, in a wide variety of liver diseases.

# 講者簡介
## Speaker Biography

### 【肝病再生醫學的進展】
【Advances in Regenerative Medicine for Liver Disease】

**Fotios Sampaziotis 教授**
Prof. Fotios Sampaziotis

劍橋大學英國研究與創新 (UKRI) 未來領導研究員
UKRI Future Leaders Fellow, University of Cambridge

阿登布魯克醫院名譽顧問肝病專家
Consultant Hepatologist, Addenbrooke's Hospital

Fotios Sampaziotis教授是英国研究与创新署（UKRI）未来领袖研究员，担任剑桥大学研究组组长，同时兼任阿登布鲁克医院名誉顾问肝病专家。他毕业于雅典大学医学院，并在剑桥完成肝病学临床培训。 期间，他获得英国医学研究理事会临床研究培训奖学金，在剑桥干细胞研究所攻读博士学位，随后以英国国家健康研究所临床讲师身份，在Ludovic Vallier教授的指导下继续从事肝病学博士后研究。

Fotios Sampaziotis教授的研究融合生物工程、细胞与基因疗法及体外灌注人体器官技术，致力于开发治疗肝病的颠覆性再生医学解决方案。其在再生医学领域的成就获得国际认可，屡获殊荣，包括“科学与赛多利斯再生医学奖”、英国移植学会“梅达沃奖章”以及“2025年欧洲胃肠病学联合会研究奖”。他积极参与多个国际联盟与理事会，例如欧洲肝脏研究学会再生肝病学联盟。他担任欧洲细胞治疗与器官再生分会理事会主席，奥斯陆大学客座教授，并在英国国民保健服务血液与移植器官捐献研究部担任肝脏研究主题负责人。为了推动研究成果向临床产品转化，福蒂奥斯联合创立了生物技术初创公司Bilitech有限公司，该公司曾入围《Nature》与默克公司衍生产业奖决赛，目前他兼任公司首席执行官。

Prof. Fotios Sampaziotis is a UK Research and Innovation (UKRI) Future Leaders Fellow at the University of Cambridge and an honorary consultant hepatologist in Addenbrooke's hospital. He obtained his medical degree from the University of Athens and completed his hepatology clinical training in Cambridge. In parallel, he secured an MRC Clinical Research Training Fellowship towards a PhD degree in the Cambridge Stem Cell Institute and continued his post-doctoral research as an NIHR Clinical Lectureship in Hepatology with Prof Ludovic Vallier in Cambridge.

Prof. Fotios' research combines bioengineering, cell and gene therapy and human organs perfused ex-vivo to develop new disruptive regenerative medicine solutions for liver disease. His work in regenerative medicine has received international recognition with multiple awards including the Science and Sartorius Award for Regenerative Medicine, the British Transplantation Society Medawar Medal and the UEG Research award (2025). He serves as an active member of multiple international consortia and governing boards, including the EASL Regenerative Hepatology consortium. He is the chair of the European Cell Therapy and Organ Regeneration Section (ECTORS) governing board, a visiting Professor in the university of Oslo and theme lead for liver research in the NHS Blood and Transplant Research Unit on Organ Donation. To translate his research into clinical products, Fotis co-founded Bilitech ltd, a startup biotechnology company listed as finalist in the Nature and Merck spinoff prize and is currently acting as CEO of the company.

# 講者簡介
## Speaker Biography

### 【代謝失調相關脂肪性肝病的基因學研究與RNA干預藥物的開發】
【Genomics of Metabolic Dysfunction-associated Steatotic Liver Disease and discovery of RNA drugs as interventions】

**Huck-Hui Ng 教授**
Prof. Huck-Hui Ng

新加坡科技研究局研究與人才發展助理行政總裁
Assistant Chief Executive for Research and Talent Development,Agency for Science, Technology and Research

新加坡科技研究局分子與細胞生物學研究所(IMCB)首席科學顧問
Chief Scientific Advisor Agency for Science of the Institute of Molecular and Cell Biology (IMCB), Technology and Research

Huck-Hui Ng教授現任新加坡科技研究局研究與人才發展助理首席執行官。

Huck-Hui Ng教授在基因調控與基因組學領域享有盛譽，曾擔任多個行政職務，包括新加坡基因組研究所執行董事、新加坡科技研究局研究生院執行董事以及生物醫學研究理事會助理首席執行官。

Huck-Hui Ng教授協助設立並實施了多項國家級資助計畫，包括新加坡食品故事計畫、人類潛能產前與早期兒童計畫以及核酸治療計畫。

Huck-Hui Ng教授活躍於科研領域，並擔任新加坡科學中心、新加坡國立大學附屬中學等機構董事會成員，以及多個研發資助指導委員會委員。

為表彰其科學貢獻，吳教授榮獲眾多本地及國際榮譽與獎項。

Professor Huck-Hui NG is the Assistant Chief Executive of Research and TalentDevelopment (R&TD), under the Agency for Science, Technology and Research.

Professor Ng is renowned in the field of gene regulation and genomics. He had held several administrative positions. He served as the Executive Director of the Genome Institute of Singapore, the Executive Director of the A*STAR Graduate Academy and the Assistant Chief Executive of Biomedical Research Council.

Professor Ng helped to setup and implement several national funding initiatives such as the Singapore Food Story, Prenatal and Early Childhood for Human Potential and Nucleic Acids Therapeutics.

Professor Ng is active in research and sits on several boards such as Science Center Singapore and NUS High School, and R&D funding steering committees.

In recognition of his scientific contributions, Professor Ng has received numerous local and international honours and awards.

# 講者簡介
## Speaker Biography

### 【骨骼架構藍圖：骨細胞譜系及其微環境的遺傳與發育調控】
【The Blueprint of Bone Architecture: Genetic and Developmental Control of skeletal Cell lineages and Neighborhoods】

**謝賞恩 教授**
Prof. Kathryn Song Eng Cheah

香港科學院院士
Fellow of the Hong Kong Academy of Sciences

香港大學生物化學系榮譽教授
Honorary Professor, Department of Biochemistry, The University of Hong Kong

謝賞恩教授是香港大學生物化學榮譽講座教授，她的成就備受肯定，於2000年獲頒裘槎資深研究員獎及鄧鉅明伉儷基金教授席（分子遺傳學）。2013年獲選爲世界科學院院士、2021年當選為香港科學院院士。於2023年，她獲選為歐洲分子生物組織(European Molecular Biology Organization，EMBO) 外籍會士，以表揚其在生物醫學領域上的卓越學術成就。謝賞恩教授是國際知名的發育生物學家，研究聚焦於骨骼和內耳發育的功能基因組學及發育遺傳學，以及人類先天性及退化性骨骼疾患的分子病理學。她的目標是將基礎研究成果轉化為治療方案，改善如骨關節炎和骨質疏鬆等疾病的治療方法。

謝教授積極參與各種科學職務，不僅擔任香港保健及醫學研究基金會和香港大學資助局研究評估小組的成員，還擔任GRC評估委員會委員，以及擔任eLife 的資深編審，在國際分子生物學界備受肯定。她熱愛科學交流，組織高等研究所和國際研討會，積極提升香港在國際科學界的形象。她成功領導爭取2025年國際幹細胞研究學會年會舉辦於香港，並榮幸擔任聯合計劃主席。

Prof. Kathryn Cheah is Emerita Chair of Biochemistry and Professor at The University of Hong Kong. She has received numerous honours, including the Croucher Foundation Senior Fellowship and the Jimmy & Emily Tang Endowed Professorship in Molecular Genetics. She has been honored by election as a Fellow of The World Academy of Sciences and a Member of the Hong Kong Academy of Sciences. In 2023, she was elected an Associate Member of EMBO. She received the British Society for Matrix Biology Medal Lecture 2022 for her contributions to matrix biology.

As a developmental geneticist, her research focuses on genomic and regenerative medicine, particularly in ageing, skeletal system disorders, and the inner ear. Her goal is to translate fundamental discoveries into treatments for conditions like osteoarthritis and osteoporosis.

Prof. Cheah is active in various scientific roles, including panel memberships for the Hong Kong Health and Medical Research Fund and the Hong Kong University Grants Council Research Assessment panel. She also serves on the Gordon Research Conferences Evaluation Committee. She is also Senior Editor for eLife. Passionate about science communication, she organises Advanced Study Institutes and international symposia, contributing to advancing Hong Kong's international scientific profile. She successfully led the bid to bring the 2025 Annual Meeting of the International Society for Stem Cell Research to Hong Kong and is co-Programme Chair.

# 講者簡介
## Speaker Biography

### 【結合再生醫學,多組學及人工智能平台開展改善慢性肝病纖維化的標靶發現及精準干預新診療 進度報告】
【FDCT AKP Progress Report】

**譚廣亨 講座教授**
Chair Prof. Paul Kwong-Hang Tam

澳門科技大學副校長
Vice President, Macau University of Science and Technology

精準再生醫學研究中心總監
Director, Precision Regenerative Medicine Research Centre (PRMRC)

現任澳門科技大學副校長，香港大學名譽教授及榮譽臨床教授。為一名蜚聲國際的外科醫生、科學家及大學領導。譚教授於2003年至2015年擔任香港大學副校長（研究），2015至2019年擔任首席副校長，並於2018年2月至7月在任其間擔任署理校長。

譚教授致力研究及發展小兒微創手術及先天性巨大結腸症等先天缺陷的基因及再生治療，在理解膽道閉鎖的疾病機制方面更取得了空前突破，為治療這些難治性小兒胃腸道疾病在個人化醫療和再生醫學層面上奠定了紮實的基礎。他發表超過501篇研究論文，其研究共獲得32716次引用，H指數高達61.

譚教授獲頒Denis Browne金獎，是英國小兒外科醫師協會的最高榮譽獎項。他於2020獲歐洲小兒外科醫師協會頒授Rehbein Medal卓越成就獎，是亞洲首位獲此殊榮的小兒外科教授。2021年，他被任命為香港科學院院士，這是香港的官方機構，相等於國內和國際類同院士認可地位，院士為終身制，是同儕頒授的最高科學家榮銜。

譚教授致力推動及提升發展中國家的小兒外科技術水準。他成立數項培訓計劃，透過一系列課程已孕育超過3000多名中國小兒外科醫生，以達致教育及醫療上深遠的影響。

Professor Paul Kwong Hang TAM, JP; MBBS(HK); ChM(Liv); FRCS(Eng, Edin, Glas, and Ire); FRCPCH; FHKAM (Surgery);HKAS member, is a surgeon, scientist, educator and university leader. He is Chair Professor and Vice-President of the Macau University of Science and Technology, and Emeritus Professor and Honorary Clinical Professor of the University of Hong Kong.

After graduation from the University of Hong Kong in 1976, he worked in the Department of Surgery until 1986. He was Senior Lecturer at the University of Liverpool in 1986-90, Reader and Director of Paediatric Surgery at the University of Oxford in 1990-96, and Chair of Paediatric Surgery (1996-2022) and Li Shu-Pui Professor in Surgery (2013-2022) at the University of Hong Kong. He was the Vice- President for Research (2003-2015), Provost and Deputy Vice- Chancellor (2015-March 2019) and Acting President and Vice-Chancellor (February – July 2018) of the University of Hong Kong.

Professor Tam has special interests in minimal invasive surgery, genetics and regenerative medicine of birth defects especially Hirschsprung's disease and biliary atresia. He has published over 500 articles in internationally refereed journals with 32716 citations and h-index = 61, and has been awarded grants totaling > US$28m. He serves on many international professional associations and was President of the Pacific Association of Paediatric Surgeons (2008-2009). He also serves on numerous international journals including the Journal of Pediatric Surgery (Editor for Pacific Region), the Lancet Child and Adolescent Health (International Advisory Board Member) and Stem Cells Translational Medicine. He has given invited lectures at Nature Forum, Days of Molecular Medicine and international associations of pediatric surgeons. He has received numerous awards including the BAPS (British Association of Paediatric Surgeons) Prize, Honorary Fellowship of the American Surgical Association, the 2017 Denis Browne Gold Medal- the highest award of the BAPS, the 2020 Rehbein Medal by the European Paediatric Surgeons' Association. He was appointed the Lancet's Series Lead for the Surgical Series of two articles and one comment on Paediatric Surgery published on 9 September 2017. In 2021, he was appointed a fellow of the Hong Kong Academy of Sciences, an official body of Hong Kong equivalent to its domestic and international counterparts.

He has led several projects to develop paediatric surgery in less affluent communities especially in China in the past two decades nurturing some 3000 paediatric surgeons in Train-the- Trainers programme and Workshops in Laparoscopic Surgery and Scientific Writing. He is happily married to Amy for 40 years with 2 lovely daughters and a grandson.

# 講者簡介
## Speaker Biography

### 【幹細胞與再生醫學技術革新與臨床安全保障體系構建】
【Building a Safe and Efficacy System for Stem Cell Technologies】

**文學軍 教授**
Prof. Xuejun Wen

維吉尼亞聯邦大學
Virginia Commonwealth University

文學軍教授於2003年在美國猶他大學生物醫學工程系(Department of Bioengineering)博士畢業後留美在世界生物材料研究發源地美國克萊姆森大學(Clemson University)任終身制教席(Tenure-Track faculty)，3年半後(2008年)獲得終身席教職(Faculty with Tenure)，2年後(2010年)，提升為正教授和南卡州政府命名的Hansjörg Wyss冠名首席終身席正教授（Hansjörg Wyss Endowed Chair Professor）。2003年創建了“克萊姆森大學和南卡醫科大學聯合生物醫學工程中心(Joint Bioengineering Program between Clemson University and Medical University of South Carolina)”。

2012年起為美國維吉尼亞醫學院/維吉尼亞聯邦大學(Medical College of Virginia/Virginia Commonwealth University)的William Goodwin冠名首席終身席正教授（William Goodwin Endowed Chair Professor），任該校生物製造實驗室主任，再生醫學實驗室主任。創立同濟大學納米醫學與生物工程研究院，山東省幹細胞與再生醫學技術創新中心，日照市幹細胞轉化醫學工程技術研究中心，日照市中醫藥現代化技術創新中心，和清華大學河北研究院幹細胞與再生醫學技術創新中心，主持和參與40多科研專案，總經費超過5000 萬美元。

文學軍教授是美國醫學與生物工程院（American Institute for Medical and Biological Engineering）的院士（2012年當選）。發表180多篇論文。2008年獲美國國家科學基金(National Science Foundation)傑出青年科學家獎（NSF CAREER）。在Elsevier資料庫發佈的“2014年中國高被引學者榜單”中，位居生物醫學工程領域第一名。繼續蟬聯2015,2016，2017，2018，2019,2020年Elsevier資料庫發佈的生物醫學工程或臨床醫學領域的“中國高被引學者”。文學軍教授開發了190多項新技術，部分技術已經產業化。

Professor Xuejun Wen had earned his Ph.D. in 2003 from the Department of Bioengineering at the University of Utah, USA. After that, he stays in the United States and joined Clemson University, the birthplace of global biomaterials research, as a Tenure-Track faculty member. Within three and a half years (2008), he was granted with Faculty with Tenure. Two years later (2010), he was promoted to professor and appointed as the Hansjörg Wyss Endowed Chair Professor, a distinguished endowed professorship named by the state of South Carolina. In 2003, he founded the Joint Bioengineering Program between Clemson University and the Medical University of South Carolina.

Since 2012, he has served as the William Goodwin Endowed Chair Professor at the Medical College of Virginia/Virginia Commonwealth University, where he also directs the Biomanufacturing Laboratory and the Regenerative Medicine Laboratory. Professor Wen has played a pivotal role in establishing several research institutions, including the Institute of Nano-Medicine and Bioengineering at Tongji University, the Shandong Provincial Technology Innovation Center for Stem Cell and Regenerative Medicine, the Rizhao Stem Cell Translational Medicine Engineering Technology Research Center, the Rizhao Modernization of Traditional Chinese Medicine Technology Innovation Center, and the Stem Cell and Regenerative Medicine Technology Innovation Center at Tsinghua University Hebei Research Institute. He has led or participated in over 40 research projects, with total funding exceeding $50 million.

Professor Wen Xuejun was elected as a Fellow of the American Institute for Medical and Biological Engineering in 2012. He has published more than 180 research papers. In 2008, he received the prestigious NSF CAREER Award from the National Science Foundation. According to the Elsevier Citation Database, he ranked first in the field of Biomedical Engineering in the "2014 List of Highly Cited Chinese Researchers" and continued to be recognized as a "Highly Cited Chinese Researcher" in the fields of Biomedical Engineering or Clinical Medicine from 2015 to 2020. Additionally, Professor Wen has developed over 190 new technologies, some of which have already been commercialized.

# 講者簡介
## Speaker Biography

**【幹細胞治療引領再生醫學領域的新時代】**
【Stem Cell Therapy: Leading a New Era in Regenerative Medicine】

### 羅雲 先生
Mr. Yun Luo

四川眾生集團董事長
Chairman of Sichuan Zhongsheng Group
成都拜美森生物科技有限公司
Chengdu Biomason Biotechnology Co., Ltd.

羅雲先生現任四川眾生集團董事長，外科醫生。中國人民大學MBA學位。澳門中華醫學會中醫協會名譽會長、四川省醫藥發展促進會副會長、涼山州僑商聯合會副會長、四川省醫學會細胞生物治療專委會常委、四川省中醫藥資訊學會理事、成都市健康管理學會理事。1994加盟上市公司四川迪康醫藥科技股份有限公司，系幾大創始人之一。2017年創立四川眾生集團，集團以醫療科技大健康全產業鏈閉環為核心發展理念。

Mr. Luo Yun is the Chairman of Sichuan Zhongsheng Group, surgeon. Holds an MBA from Renmin University of China. Honorary President of the Macau Chinese Medical Association Chinese Medicine Association, Vice President of the Sichuan Provincial Pharmaceutical Development Promotion Association, Vice President of the Liangshan Prefecture Overseas Chinese Business Association, Standing Committee Member of the Cell Biotherapy Committee of the Sichuan Medical Association, Council Member of the Sichuan Provincial Traditional Chinese Medicine Information Society, and Council Member of the Chengdu Health Management Association. Joined the listed company Sichuan DiKang Pharmaceutical Technology Co., Ltd. in 1994 as one of its key founders. Founded Sichuan Zhongsheng Group in 2017, with the group's core development philosophy centered on creating a closed-loop ecosystem across the entire healthcare industry chain.

### 尚進 博士
Dr. Jin Shang

成都拜美森生物科技有限公司
Chengdu Biomason Biotechnology Co., Ltd.

現任四川大學華西臨牀醫學院助理研究員、博士，同時兼任四川省腫瘤醫院實驗動物中心技術主管及成都拜美森生物科技有限公司研發顧問。在學術服務方面，擔任四川省醫學會醫學細胞生物學青年委員會副主任委員。其主要研究方向爲幹細胞與免疫細胞的臨牀轉化應用，致力於推動前沿細胞治療技術的臨床落地。已在《Journal of Nanobiotechnology》、《Hepatology》、《International Immunopharmacology》等國際知名期刊發表學術論文10餘篇，並參與或主持了包括國家自然科學基金及四川省科技廳自然科學基金在內的多項科研項目。

Dr. Jin Shang serves as an Assistant Researcher and Ph.D. at the West China School of Medicine, Sichuan University. Concurrently, he/she holds the position of Technical Director at the Laboratory Animal Center of Sichuan Cancer Hospital and works as a Research & Development Consultant for Chengdu Baimeisen Biological Technology Co., Ltd. He also contributes to academic governance as the Deputy Director of the Youth Committee of Medical Cell Biology within the Sichuan Medical Association. His primary research focuses on the clinical translation and application of stem cell and immune cell therapies. With a strong publication record, he/she has authored more than 10 papers in prestigious international journals such as Journal of Nanobiotechnology, Hepatology, and International Immunopharmacology. His research has been supported by several competitive grants, including projects from the National Natural Science Foundation of China and the Natural Science Foundation of Sichuan Province.

# 講者簡介
## Speaker Biography

### 【新生兒臍帶幹細胞在再生與長壽醫學的應用】
【Neonatal Stem Cells derived From Umbilical Cord Tissue for Regenerative and Longevity Medicine】

**潘全勝 副教授**
Assoc. Prof. Toan Thang Phan

新加坡國立大學創傷癒合與幹細胞研究組副教授兼首席研究員
Associate Professor and Principal Investigator of the Wound Healing and Stem Cell Research Group, National University of Singapore

CellResearch集團首席科學官
CSO of CellResearch Corporation Group of Companies

潘博士1991年畢業於越南河內軍事醫科大學，自醫學科研生涯伊始便對傷口癒合領域展現出濃厚興趣。這份熱忱促使他在河內國家燒傷中心及103軍醫院創傷外科的四年外科住院醫師期間積累了豐富的實踐經驗。

潘博士在實驗室研究領域的奉獻精神與卓越成就，在其于英國牛津大學享有盛譽的傷口癒合研究所及皮膚病學系進行為期兩年的深造期間得到了充分印證。

他於1997年抵達新加坡，加入新加坡中央醫院整形外科。1998年，他結識了林艾佛醫生，兩人共同創立了傷口癒合與幹細胞研究小組，專注於皮膚與瘢痕疙瘩生物學研究。該研究組是全球首個探索上皮–間質相互作用在瘢痕疙瘩發病機制中作用的研究團隊，如今已成為全球瘢痕疙瘩與瘢痕生物學研究領域的頂尖團隊之一。

在擔任新加坡國立大學楊潞齡醫學院外科系教職之前，潘博士曾在斯坦福大學幹細胞與再生醫學研究所完成為期兩年的博士後研究。

作為傑出的學術研究者與企業家，潘博士已在國際同行評審期刊發表逾80篇論文及兩本專著章節，擁有80餘項授權專利，並在新加坡與越南創立多家成功的生物科技及醫療企業。其近期突破性研究成果在於臍帶內膜中發現了一種新型幹細胞來源，該發現具有轉化為再生醫學、組織工程和細胞療法的潛力。

A graduate of the Military Medical University, Hanoi, Vietnam in 1991, Dr Phan has had a strong interest in wound healing since the earliest days of his medical and scientific career. His interest led him to hands-on experience during his four-year surgical residency in Hanoi at the National Burns Centre and at the Department of Trauma Surgery, Military Hospital 103.

Dr. Phan's commitment and excellence in laboratory research was proven when he spent two years at the prestigious Wound Healing Institute and Department of Dermatology in Oxford, England.

He arrived in Singapore in 1997 to join the Department of Plastic Surgery at the Singapore General Hospital. In 1998, he met Dr Ivor Lim, and together they established the Wound Healing and Stem Cell Research Group focusing on skin and keloid scar biology. The Wound Healing and Stem Cell Research Group was the first group in the world to explore the role of epithelial-mesenchymal interactions in keloid pathogenesis and is recognised today as one of the world leading groups in keloid and scar biology research.

Prior to taking up his faculty position at the Department of Surgery, Yong Loo Lin School of Medicine at the National University of Singapore, Dr. Phan completed two years of post-doctoral research at the Stanford University Institute for Stem Cell Research and Regenerative Medicine

As a successful academic researcher and entrepreneur, Dr. Phan is author of more than 80 publications in international peer-reviewed journals, two book chapters, has more than 80 granted patents and founder of multiple successful biotech and healthcare companies in Singapore and Vietnam. His recent innovative research work is the discovery of a novel source of stem cells from the umbilical cord lining membrane with translational potential for regenerative medicine, tissue engineering and cell-based therapy.

# 講者簡介
## Speaker Biography

### 【CAR-T療法的進展：從自體細胞到體內載體遞送的研究前沿】
【Advances in CAR-T development ---from autologous cells to in vivo vehicle delivery】

**林成龍 教授**
Prof. Steve Chen Lung Lin

臺灣沛爾生技醫藥股份有限公司董事長
Chairman of Pell Bio Med Technology Co., Ltd.

林成龍教授，擁有英國牛津大學臨床醫學博士 DPhil (Oxon)，身兼英國倫敦帝國學院外科 學院講座教授、香港大學外科學院與病理學榮譽教授，同時也是英國皇家外科學院院士 FRCS (Eng)。林成龍於英國牛津大學攻讀免疫學博士時期，便開始接觸並深入癌症免疫細胞治療、及脂肪幹治療技術之研究與臨床應用。2011 年，林成龍教授將他在國外多年寶貴的學術研究與臨床經驗帶回台灣，奠定基礎，期許成為細胞治療與再生醫學方面的領航者。2017年3月，創立沛爾生醫於高雄，為台灣少數專營細胞培養之基因改造及細胞治療之臨

床應用的生技公司。隨著公司成長，於 2019 年 5 月在台北市內湖科學園區成立企業總部，現今研發團隊屢屢榮獲國家新創獎等殊榮，並持續推動與多個研究單位包含中研院、國衛院、工研院、紡研所等、及醫療院所合作，展現其精準、專業的經營理念。

Professor Cheng-Lung Lin holds a Doctor of Philosophy (DPhil) in Clinical Medicine from the University of Oxford. He is a Chair Professor at the Department of Surgery, Imperial College London, an Honorary Professor in the Departments of Surgery and Pathology at the University of Hong Kong, and a Fellow of the Royal College of Surgeons of England (FRCS Eng).

During his doctoral studies in immunology at the University of Oxford, Professor Lin began exploring cancer immunotherapy and adipose-derived stem cell therapy, focusing on both research and clinical applications. In 2011, he returned to Taiwan, bringing his extensive academic and clinical experience to lay the foundation for becoming a leader in cellular therapy and regenerative medicine.

In March 2017, he founded Pell Biotech in Kaohsiung, one of Taiwan's few biotech companies specializing in cell culture, genetic engineering, and clinical applications of cell therapy. As the company expanded, a corporate headquarter was established in May 2019 at the Neihu Science Park in Taipei. Today, the research and development team has garnered numerous national innovation awards and continues to collaborate with multiple research institutes, including Academia Sinica, the National Health Research Institutes, the Industrial Technology Research Institute, and the Taiwan Textile Research Institute, as well as various medical institutions. These efforts reflect the company's commitment to precision and professionalism in its business philosophy.

# 講者簡介
## Speaker Biography

**【調節性T細胞療法在自身免疫疾病的突破探索】**
【The Exploration of Treg-based Immuno-therapies for Autoimmune Diseases】

**劉峰 博士**
Dr. Tony Feng Liu

博迪賀康(北京)生物技術有限公司
Benethera Biotechnology Co., Ltd.

劉峰博士畢業于加拿大多倫多大學（University of Toronto），獲得製藥學博士學位，現任博迪賀康生物技術有限公司首席運營官。

劉博士深耕醫藥研發領域近二十年，專注腫瘤、自免、內分泌及細胞治療等領域藥物研發。歸國前，任職于勃林格殷格翰（Beohringer Ingelheim）、阿斯利康（AstraZeneca）北美研發總部，從事臨床開發工作；歸國後歷任華東醫藥、上海馴鹿生物高級研發管理崗位，積累了中外頂尖企業豐富的研發管理經驗。其主導或參與全球20個國家與地區的80余項臨床研究，推動13款藥物實現國內外上市；研究成果發表於《Drug Metabolism Pharmacokinetics》等國際製藥學期刊，累計十餘篇。

Dr. Feng Liu received his Ph.D. in Pharmaceutical Science from the University of Toronto and now serves as the Chief Operating Officer of Benethera Biotechnology Co., Ltd.

With nearly two decades of experience in pharmaceutical R&D, Dr. Liu has focused on drug development in the fields of oncology, autoimmune diseases, endocrinology, and cell therapy. Before returning to China, he worked at the Oncology Global Hub of AstraZeneca and Boehringer Ingelheim Canada, specializing in clinical development. After returning to China, he held senior R&D management positions at Huadong Medicine and IASO BioTherapeutics, accumulating extensive R&D management experience from top-tier Chinese and multi-national pharmaceutical companies.

He has led or participated in over 80 clinical studies across 20 countries and regions, driving 13 drugs to market both domestically and internationally. His research achievements have been published in international pharmaceutical journals such as *Drug Metabolism and Pharmacokinetics*, with more than a dozen publications in total.

# 講者簡介
## Speaker Biography

### 【個性化mRNA 腫瘤疫苗的開發和應用】
【Personalized mRNA Tumour Vaccines: From Development to Clinical Use】

**陳立 博士**
Dr. Li Chen

北京立康生命科技有限公司
Likang Life Sciences

陳立博士爲立康生命科技創始人、董事會主席兼首席執行官。陳立博士本科畢業于北京理工大學，並於中國科學院生物物理研究所獲得博士學位。他曾在北京大學腫瘤醫院進行臨床醫學博士後研究。陳博士在T細胞免疫和腫瘤免疫治療的產業化方面有多年的經驗。

北京立康生命科技有限公司是一家自主研發，擁有自主知識產權，開發以腫瘤新生抗原（Neoantigen）爲靶標的個性化腫瘤疫苗和T細胞藥物的創新型企業。宗旨是以國際最前沿的精準診斷技術、mRNA藥物技術和細胞藥物開發平臺，針對未被滿足的臨床需求，開發“First-in-Class”抗腫瘤創新藥物。公司開發的個性化腫瘤新生抗原疫苗產品——LK101注射液是中國首個獲得NMPA批準進入臨床階段的個性化腫瘤新生抗原疫苗，也是中國首個獲批進入臨床階段的完全個性化的mRNA編輯產品，2025年又成為國內首個在FDA獲批臨床的個性化mRNA腫瘤疫苗。

公司的目標是建立理念超前、技術領先的國際一流個性化腫瘤藥物研發、生產中心，引領癌症治療進入真正的個性化腫瘤免疫治療新時代。

Dr. Chen is the Founder, Chairman and CEO of Likang Life Sciences. He graduated from Beijing Institute of Technology, and then graduated from the Institute of Biophysics of the Chinese Academy of Sciences with a Ph.D.'s degree. He had been working as a postdoctoral researcher in clinical medicine at the Peking University Cancer Hospital & Institute. He has a wealth of experience in industrialisation of T-cell immunity and tumour immunotherapy.

Likang Life Sciences is an innovative enterprise dedicated to development of immune cell therapy, with tumour-specific neoantigen as the target. It aims to provide personalized diagnosis and treatment services for cancer patients with the most cutting-edge precise detection and treatment methods. Its personalized tumour neoantigen vaccine, LK101, holds the distinction of being the first in China to obtain NMPA approval for clinical-stage development, as well as the first fully personalized mRNA Tumour Vaccine to be cleared for clinical trials. In 2025, it also became China's first personalized mRNA tumour vaccine to receive FDA approval for clinical trials.

The company's goal is to establish a top cancer treatment center with advanced concepts, leading technologies and standardized services, and lead cancer treatment into a new era of personalized tumor immunotherapy..

## 贊助/支持
## Sponsor/Support

### 北極光一人有限公司
### *Aurora Borealis Co., Ltd.*

北極光一人有限公司總部設立在深圳（深圳市北極光進出口科技有限公司），並分別在香港、澳門、珠海、廣州、佛山、東莞等地設立辦事處，是一家致力於實驗室整體服務解決方案的供應商。我司擁有多年實驗室規劃經驗的專業團隊，以使用者的實驗內容為導向，從實驗室諮詢設計、預算規劃、裝修、儀器及耗材試劑提供、儀器維修保養、認證服務等為使用者提供一整套實驗室解決方案。

本公司供應性價比高的國內外實驗基礎儀器、生命科學分析儀器、材料化工分析測試儀器等給政府、醫院、大學、科研院所、藥廠以及企業等。公司與多家世界知名精密儀器製造商具有多年合作經驗，包括但不限於：ZEISS、Bruker、ESCO、Agilent、Sartorius、Labconco、SHIMADZU、Alphavita、HITACHI、PerkinElmer、JEOL、Anton Paar、AMETEK、Eppendorf、Binder、Bio-Rad、QD、紐邁核磁、中科美菱、天津語瓶、新羿生物等國內外知名品牌，同時擁有部分儀器廠家代理授權書。

Aurora Borealis Sci-Tech Co.,Ltd. is headquartered in Shenzhen and has offices in Hong Kong, Macau, Zhuhai, Guangzhou, Foshan, Dongguan and other places. It is a supplier dedicated to providing comprehensive laboratory service solutions. Our company has a professional team with years of experience in laboratory planning, guided by the user's experimental content, providing a complete set of laboratory solutions for users from laboratory consulting design, budget planning, decoration, instrument and consumable reagent supply, instrument maintenance, certification services, etc.

Aurora Borealis Sci-Tech Co.,Ltd provides cost-effective domestic and international experimental basic instruments, life science analysis instruments, materials and chemical analysis and testing instruments to governments, hospitals, universities, research institutes, pharmaceutical factories, and enterprises. The company has many years of cooperation experience with several world-renowned precision instrument manufacturers, including but not limited to: ZEISS, Bruker, ESCO, Agilent, Sartorius, Labconco, SHIMADZU, Alphavita, HITACHI, PerkinElmer, JEOL, Anton Paar, AMETEK, Eppendorf, Binder, Bio Rad, QD, Newman Nuclear, Zhongke Meiling, Tianjin Yuping, Xinyi Biological and other well-known domestic and foreign brands, At the same time, we have authorization letters from some instrument manufacturers to act as agents.

## 贊助/支持
## Sponsor/Support

# 廣州安邦生物科技有限公司
# *Guangzhou abbiotechnology, Inc.*

廣州安邦生物科技有限公司成立於2011年6月，坐落於廣州市天河區怡祥大地公園，擁有1600多平方米的現貨試劑耗材及儀器倉庫，擁有專業的試劑冷庫及配套冷鏈物流配送服務，是一家華南地區專業提供生命科學實驗室產品和服務的供應商。公司主營業務涉及生物技術、生物醫藥、分子診斷、分析檢測等領域，現階段產品涵蓋了細胞生物學、免疫學、分子生物學、表觀遺傳學、蛋白純化、生化試劑等，產品線日趨完善。

安邦生物專業為客戶提供個性化和定制化的一站式科研實驗室產品解決方案，以及穩定可靠的技術支持與售後服務。

Guangzhou Abiotechnology, Inc. was established in June 2011 and is located in Yixiang Dadi Park, Tianhe District, Guangzhou. It boasts a warehouse of over 1,600 square meters for ready-to-use reagents, consumables, and instruments, along with a professional reagent cold storage facility and supporting cold chain logistics and distribution services. As a supplier specializing in life science laboratory products and services in South China, the company's main business covers biotechnology, biomedicine, molecular diagnostics, analysis and detection, among other fields. Currently, its product line includes cell biology, immunology, molecular biology, epigenetics, protein purification, biochemical reagents, and more, with a gradually improving product range.

Anbang Biotech specializes in providing customers with personalized and customized one-stop research laboratory product solutions, as well as stable and reliable technical support and after-sales service.

# 組織委員會
## Organizing Committee

主席 Chairman

譚廣亨 講座教授
Chair Prof. Paul Kwong-Hang Tam

澳門科技大學副校長
Vice President, Macau University of Science and Technology

澳門科技大學醫學部委員會主席
Chairman of Medical Sciences Division Board,
Macau University of Science and Technology

主席 Chairman

朱依諄 講座教授
Chair Prof. Yizhun Zhu

澳門科技大學協理副校長
Associate Vice President, Macau University
of Science and Technology

澳門科技大學藥學院院長
Director, School of Pharmacy, Macau University
of Science and Technology

副主席 Vice Chairman

曾致慧 博士
Dr. Chi Wai Chang

澳門科技大學醫學部總監（發展與臨床）
Director (Development and Clinical), Medical Sciences Division,
Macau University of Science and Technology

澳門科大醫院副院長兼行政總監
Vice President & Administrative Director，University Hospital

# 組織委員會
## Organizing Committee

成員 Member

吳強 教授
Prof. Qiang Wu

澳門科技大學中藥機制與質量研究國家重點實驗室教授
Professor, State Key Laboratory of Mechanism and Quality Research in of Chinese Medicine, Macau University of Science and Technology

成員 Member

陳嚴 博士
Dr. Yan Chen

澳門科技大學精準再生醫學研究中心助理總監
Assistant Director, Precision Regenerative Medicine Research Centre, Macau University of Science and Technology

澳門科技大學醫學院助理教授
Assistant Professor, Faculty of Medicine, Macau University of Science and Technology

成員 Member

潘星華 教授
Prof. Xing Hua Pan

澳門科技大學精準再生醫學研究中心教授
Professor, Precision Regenerative Medicine Research Centre, Macau University of Science and Technology

# 組織委員會
## Organizing Committee

成員 Member

蒙梓棋 博士
Dr. Olivia Monteiro

澳門科技大學醫學院助理教授
Assistant Professor, Faculty of Medicine, Macau University of Science and Technology

成員 Member

黃耀南 博士
Dr. Io Nam Wong

澳門科技大學醫學院助理教授
Assistant Professor, Faculty of Medicine, Macau University of Science and Technology

成員 Member

張瑞雪 博士
Dr. Ruixue Zhang

澳門科技大學醫學部助理教授
Assistant Professor, Medical Sciences Division, Macau University of Science and Technology

澳門科技大學
MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY

醫學部
MSD

## 精準再生醫學研究中心
## Precision Regenerative Medicine Research Centre

贊助單位: 北極光 Aurora　AB 安邦生物

## 查詢 Enquiries:


電話Tel：(853)8897 2833 / (853)8897 3411 / (853)8897 3334

傳真Fax：(853) 2899-0889

電郵 E-mail : msd@must.edu.mo

地址Address：中國澳門氹仔偉龍馬路 / Avenida Wai Long, Taipa, Macau


網址Website：www.must.edu.mo